Podcasts about Io

My podcast guest this week is Jan Zimmerman from TEWS Technologies. Jan and I are talking all about VITA 93 – a new QMC mezzanine card standard and why scalability, modularity and flexibility are central elements of this new standard. Jan and I also discuss the unique I/O capabilities of QMCs and how TEW Technologies is furthering innovation in this arena. 

SPID clonato? Ora su NoiPA serve una doppia autenticazione.Da giugno 2025 il portale NoiPA ha aggiunto un secondo livello di sicurezza: se provi entrare con uno SPID o una CNS diversi dall'originale, arriva subito una mail di verifica. Questo dopo anni di rischi: bastava una truffa per cambiare IBAN e dirottare stipendi e rimborsi su un altro conto senza che il proprietario se ne accorgesse! Si parla di milioni di utenti potenzialmente esposti e di frodi che potevano passare inosservate.Eppure quando ne avevamo parlato qualche settimana fa, molti diversamente ''esperti'' avevano gridato ''fake news!1!''. Ora a quanto pare la toppa di emergenza conferma invece i timori.E su tutti gli altri siti accessibili con SPID?~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

Bastano 20 secondi in mondovisione per vedersi crollare carriera e famiglia: la Kiss Cam becca il CEO e l'HR manager abbracciati a Boston. Il video diventa virale in meno di 1 ora, causando danni reputazionali, problemi legali in azienda e (forse) separazioni.Quando un momento “buffo” si trasforma in crisi: appena circolano nome e ruolo si rischiano licenziamenti, ondata di hate online e perfino azioni legali. Nel 2023, l'81% delle crisi social nasce da contenuti “decontestualizzati”.Ti è mai capitato di finire in video senza volerlo? Commenta come avresti reagito!

Dr. Lyudmila Bazhenova is back on the podcast to discuss the latest update of the living guideline on therapy for stage IV NSCLC without driver alterations. She shares the studies the Expert Panel reviewed in the first- and second-line settings, including NIPPON, HARMONi-2, and DUBLIN-3. Although these studies do not impact the existing guideline recommendations, Dr. Bazhenova provides context and comments on ongoing trials that will influence the next iteration of the living guideline. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1” at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01062 Brittany Harvey: Hello, and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Lyudmila Bazhenova from University of California San Diego Moores Cancer Center, co-chair on "Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1." It's great to have you back on the show today, Dr Bazhenova. Dr. Lyudmila Bazhenova: It's my pleasure to be here. Brittany Harvey: And then before we discuss this guideline update, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Bazhenova, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into the content here, Dr. Bazhenova, this living clinical practice guideline for systemic therapy for patients with stage IV non–small cell lung cancer without driver alterations is updated on an ongoing continuous basis. So what prompted this latest update to the recommendations? Dr. Lyudmila Bazhenova: Living ASCO guidelines are designed to keep pace with rapidly evolving evidence that impacts treatment of our patients with lung cancer. As a committee, we are tasked with regular review of the published literature and determine if the new data warrants changes to existing recommendations. So in this recently published update, we evaluated new trials related to treatment of patients with metastatic lung cancer without driver alterations. Brittany Harvey: Excellent. Thank you for that explanation of the process. So, you just mentioned that the panel reviewed new trials for this update. So, which particular updated evidence did the panel review on first-line treatment options for patients with good performance status across histology and PD-L1 expression status, and how did this impact the recommendations? Dr. Lyudmila Bazhenova: For the first-line treatment option for patients without driver alterations, two studies met our criteria for review. One was the NIPPON trial from Japan, the second was the HARMONi trial. None of those two trials resulted in change in our guidelines, but I think they are giving us some additional information that would be useful for the way we treat patients with non–small cell lung cancer without driver alterations. For example, if we take those patients, we currently have several treatment options as a first line. One is monotherapy immunotherapy. You can give pembrolizumab as an example, and that was based on the KEYNOTE-024 and KEYNOTE-042 trials. Then we have a platinum doublet plus immunotherapy, and there are several trials that did that pathway. And then we have also an option of giving our patients dual IO immunotherapy combination, such as CheckMate 9LA and POSEIDON. At this point, we do not have any randomized trials comparing those three treatment modalities head-to-head. And the NIPPON trial was interesting to us because it was the first trial to compare CheckMate 9LA regimen, which is again, dual immunotherapy plus chemo, versus KEYNOTE-189 or KEYNOTE-407, which is a chemotherapy plus immunotherapy. And as a result of the study, while chemotherapy plus ipilimumab-nivolumab led to numerically higher overall survival, the difference was not statistically significant. And what is concerning in that trial is that we saw a higher number of treatment-related death occurring in nivolumab and ipilimumab arm compared to the pembrolizumab-chemotherapy arm. As a matter of fact, the trial was terminated early because of the increased risk of death. If you look at the treatment-related death in CheckMate 9LA, the 9LA study reported the treatment-related death to be 2%, and then in the NIPPON trial, the treatment-related death was 7%. Why is that happening? It's really difficult to say. The study was done in Japan. Maybe there is some pharmacogenomic differences between global population and Japan population. But certainly the higher rate of adverse events needs to be taken into account. Another interesting thing about this trial is that it did not show any differences in a subset analysis for patients with squamous histology as well as PD-L1 negative tumor. So while this does not change our current guidelines and CheckMate 9LA treatment still remains an appropriate treatment option, it kind of raises the possibility that this combination could be associated with a higher toxicity. And we do have a randomized US-based trial that is ongoing, and we are hoping that eventually we will be able to answer that question after the trial will be completed. The second trial we reviewed is HARMONi-2. So HARMONi-2 was a randomized, double-blind study which is conducted primarily in China, looking at bispecific PD-L1 and VEGF antibody called ivonescimab. And that took patients who were PD-L1 positive, as defined as more than 1% expression, and patients were randomized to pembrolizumab versus bispecific ivonescimab. And the study was positive. It showed improvement in median progression-free survival of 11 months versus almost 6 months in bispecific versus pembrolizumab. There were, however, higher grade 3 events in the ivonescimab arm. At this point, we are not changing our recommendations because this trial was done in an ex-US population, and we are awaiting a similar trial ongoing in the United States before we change recommendations and decide if ivonescimab needs to be included in our guidelines. Brittany Harvey: This context is very helpful when clinicians think through the data behind these options. And it's important that the panel reviews this evidence, even if it doesn't prompt a change to the recommendations. And we'll await results of those trials that you mentioned to further inform this guideline. So then beyond those studies for first line, what updated evidence did the panel review for second-line and subsequent treatment options for patients with good performance status, and how did this impact the recommendations? Dr. Lyudmila Bazhenova: So for second line, only one trial met the criteria, and that was DUBLIN-3. DUBLIN-3 is a phase 3 single-blind randomized trial comparing docetaxel versus docetaxel plus plinabulin. And the study enrolled patients with second or third line. They have to have had platinum-based chemotherapy and progressed. Plinabulin is an interesting compound. It's a small molecule tubulin binder that prevents polymerization of tubulin and appears to impact dendritic cell maturation and T-cell activation. This study enrolled 559 patients, randomly assigned them to two groups. And one important information about this study is that was a study that was envisioned before immunotherapy became a standard mainstream treatment for first-line therapy. And only 20% of patients had prior PD-1 exposure. So therefore, the results of that study need to be taken into context of this population no longer existing in the United States because we use PD-L1 inhibitors in the first line. And we saw that interesting in the plinabulin arm had lower rates of neutropenia but higher rates of serious adverse events. And at this point, we are not changing our guidelines for mainly two reasons. Number one, low number of patients that received prior treatment with first-line immune checkpoint inhibitors, as well as a modest overall survival benefit of this trial. Brittany Harvey: Understood. I appreciate you describing that study as well and why that evidence didn't prompt a change to those particular recommendations. So then, what should clinicians know as they implement this living guideline, and how does this new evidence impact clinicians and patients? Dr. Lyudmila Bazhenova: At this point, none of the studies that we reviewed resulted in a change in guidelines. We are still waiting for more global results from some of the studies that I highlighted. It shows that there's still a lot of questions we need to be answering in those patients. And I'm hoping that with future clinical trials, we will be able to definitively maybe recommend one treatment over another. But at this point, all the treatments that I mentioned before remain appropriate for patients with stage IV non–small cell lung cancer without driver alterations. Brittany Harvey: Definitely. And then you just mentioned that there's still a lot of outstanding questions in this field. You've mentioned a couple different studies where we're awaiting evidence. Beyond those that you already mentioned, what is the panel examining for future updates to this living guideline? Dr. Lyudmila Bazhenova: Right now, our next task is to come up with a full guidelines update. ASCO have certain rules for the guidelines committee members. And so we are gearing for a full guideline update, which hopefully will be ready by the end of 2025. Brittany Harvey: Excellent. We'll look forward to that full update of the living guideline, and we'll still await results of these ongoing trials to further inform this living guideline. So I want to thank you so much for your work to rapidly and continuously update this living guideline, and thank you for the time today, Dr. Bazhenova. Dr. Lyudmila Bazhenova: My pleasure. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Microsoft ha licenziato 9000 persone in pochi giorni e ha proposto l'AI come soluzione al “malessere” post-taglio.Se affidiamo la cura delle crisi lavorative ai chatbot, le aziende trasferiscono responsabilità e rischio reputazionale direttamente sulle persone: automation bias + solitudine = crisi peggiorata.Quando 9000 dipendenti restano senza lavoro e si trovano consigli “emotivi” da chi non è stato toccato dai licenziamenti, l'impatto sociale è disastroso.Voi vi affidereste a una macchina quando serve empatia vera?~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

In the late 1990s, Italy was worried that Satanism was on the rise. There were whispers of cults and worshippers performing dark rituals to appease the devil and citizens were flocking to their churches worried about their immortal souls and the safety of their loved ones. This fear was not completely unfounded. In the outskirts of Milan, in Busto Arsizio, was a heavy metal band that had taken the idea of Satanic worship and twisted it until their desire to appease Satan turned them into killers. The Beasts of Satan terrorized the community from the shadows for years, and at least 3 people were killed in the name of the Devil, until it all came crashing down in 2004. Connect with us on Social Media!You can find us at:Instagram: @bookofthedeadpodX: @bkofthedeadpodFacebook: The Book of the Dead PodcastTikTok: BookofthedeadpodOr visit our website at www.botdpod.comFeaturing a promo for Scottish Murders:cotland's landscapes are some of the most breath-taking in the world, from the humungous mountains in the Highlands to the golden beaches strewn from coast to coast and dense forest lined roads that weave around Scotland.However, just like anywhere else in the world, scratch a little below the surface and you will find some of the most evil of killers lurking. Join us as we dive into the not so nice side of Scotland and tell you about some well known and not so well known murders, some mysterious murders, some shocking murders… all things murderous.Welcome to Scottish Murders.Listen hereABC News. (2005, February 22). Italian rocker gets 30 years for satanic killings. https://www.abc.net.au/news/2005-02-23/italian-rocker-gets-30-years-for-satanic-killings/1523594Alessiacornali. (2020, November 23). Elisabetta Ballarin: la rinascita delle Bestie di Satana. Pinkblog. https://www.pinkblog.it/2020/11/15/elisabetta-ballarin-la-rinascita-delle-bestie-di-satana/Baker, A. (2004, June 20). Italian Police Look to a Cult In '98 Killings Of Teenagers. The New York Times. https://www.nytimes.com/2004/06/20/world/italian-police-look-to-a-cult-in-98-killings-of-teenagers.htmlBBC NEWS | Programmes | This World | Investigating the “death metal” murders. (n.d.). http://news.bbc.co.uk/2/hi/programmes/this_world/4446342.stmBivins, J. C. (n.d.). How a music genre known as black metal came to be related to church burnings. The Conversation. https://theconversation.com/how-a-music-genre-known-as-black-metal-came-to-be-related-to-church-burnings-115533Campbell, R. (2018, April 11). Church of Satan History: The Church of Satan. Church of Satan. https://churchofsatan.com/cos-church-of-satan/Del Frate, C. (2024, May 4). La verità di Maccione, medium-assassino delle Bestie di Satana: «Tutto ruotava intorno alla donna. Io non mi sono mai sentito un mostro». Corriere Della Sera. https://www.corriere.it/sette/attualita/24_maggio_04/la-verita-di-maccione-medium-assassino-delle-bestie-di-satana-tutto-ruotava-intorno-alla-donna-io-non-mi-sono-mai-sentito-un-mostro-3067fce8-9152-4499-81a4-fd3687532xlk.shtml?refresh_ceDemetriou, D. (2005, January 14). Beasts of Satan's killing spree has Italy transfixed | The Independent. The Independent. https://www.independent.co.uk/news/world/europe/beasts-of-satan-s-killing-spree-has-italy-transfixed-486599.htmlDoland, A. (2005, February 26). Italian University launches course on exorcism. Chron. https://www.chron.com/life/houston-belief/article/Italian-university-launches-course-on-exorcism-1505645.phpFuqua, L. M. (2022, May 25). Beast of Satan Murders in Italy | True Crime - True crime Addiction - Medium. Medium. https://medium.com/true-crime-addiction/beast-of-satan-murders-in-italy-true-crime-5b1a7c1cc8a1Giacomazzo, B. (2025, January 6). The Beasts of Satan and their cult murders that shocked Italy. All That's Interesting. https://allthatsinteresting.com/beasts-of-satanGravereviewer. (2022, April 2). Beasts of Satan: An Italian band gone wrong - Grave reviews - True crime. Grave Reviews. https://gravereviews.com/2020/09/17/beasts-of-satan-an-italian-band-gone-wrong/Hooper, J. (2018, March 4). Beasts of Satan band members jailed for killings. The Guardian. https://www.theguardian.com/world/2005/feb/23/italy.artsIrishExaminer.com. (2020, May 21). Heavy metal band members jailed for Satanic murders. Irish Examiner. https://www.irishexaminer.com/world/arid-30190523.htmlJohn Aylward. (2023, July 15). Occult Crimes S01E06 Beasts of Satan 02 [Video]. YouTube. https://www.youtube.com/watch?v=qY1vnzf82uQLa Barbera, P. (2020, April 28). Due chiacchiere con Michele Tollis - “Ancora oggi torno nel bosco” - Sdangher! 2.0. Sdangher! 2.0. https://www.sdangher.com/2020/04/28/michele-tollis/Phillips, J. (2004, July 30). Satanists accused of ordering serial killings. The Independent, 28.Popham, P. (2004a, June 10). Fourth Milan death linked to Satanist rock band | The Independent. The Independent. https://www.independent.co.uk/news/world/europe/fourth-milan-death-linked-to-satanist-rock-band-731779.htmlPopham, P. (2004b, June 23). Cemetery staff “suicides” linked to satanic cult by Italian investigators. The Independent, 25.Popham, P. (2004c, October 13). Satanic gang leader's diary sheds light on murder case. The Independent, 26.Tst. (n.d.). About us. TST. https://thesatanictemple.com/pages/about-usVolpini, L., AAFS, Cipollaro, G., Garofano, L., & Borrini, M. (2017). Youth Satanism and forensic investigation: The case of the “Beasts of Satan” in Italy. In Psychiatry & Behavioral Science. https://www.aafs.org/sites/default/files/media/documents/AAFS-2017-I19.pdfWeirdItaly. (2023, February 25). The Beasts of Satan: a cult responsible for multiple murders. Weird Italy. https://weirditaly.com/2014/06/29/the-beasts-of-satan-the-most-sordid-satanic-murders-in-italy/Wilkinson, T. (2019, March 2). Italy's “Beasts of Satan” face murder trial - Los Angeles Times. Los Angeles Times. https://www.latimes.com/archives/la-xpm-2005-jan-30-fg-satanic30-story.htmlWilson, S. R. (2019, March 8). Turin Is Getting a Devil of a Time : Religion: The city has a reputation as a haven for Satan and his disciples. The Catholic Church has six exorcists on duty. - Los Angeles Times. Los Angeles Times. https://www.latimes.com/archives/la-xpm-1990-06-17-mn-166-story.html

Today, we're talking Valkey, Redis, and all things caching. Our guest is Madelyn Olson, who is a principal engineer at AWS working on Elasticache and is one of the most well-known people in the caching community. She was a core maintainer of Redis prior to the fork and was one of the creators of Valkey, an open-source fork of Redis. In this episode, we talk about Madelyn's road to becoming a Redis maintainer and how she found out about the March 2024 license change. Then, Madelyn shares the story of Valkey being created, philosophical differences between the projects, and her reaction to re-relicensing of Redis in May 2025. Next, we dive into the performance improvements of recent Valkey releases, including the I/O threads improvements and the new hash table layout. Along the way, Madelyn dispels the notion that the single-threaded nature of Redis / Valkey is that big of a hindrance for most workloads. Finally, she compares some of the Valkey improvements to some of the other recent cache competitors in the space.

Questa mattina mi sono alzato con una voglia incredibile di indossare una collana che ho comprato anni fa in Salento. Poi, considerando il fatto che non indosso mai collane o bigiotteria in genere, mi sono chiesto se fosse il caso. Io penso che ognuno dev'essere libero di fare ciò che sente, indipendentemente dall'età, ma deve anche sapersi guardare allo specchio. Ci sono indumenti o accessori, come può essere una collana, che se indossati da chi li sa indossare fanno la loro bella figura ma se indossati da chi non li sa indossare o non ha il fisico adatto possono creare un effetto assolutamente contrario. Fatte queste considerazioni sono arrivato alla conclusione che la mia collana è bellissima ma forse è meglio che la lascio portare a chi la sa portare. Ascolta il podcast di NON E' LA SIESTA, troverai questo e altri argomenti dal sapore estivo. Riccardo.

Io sono Francesco Cecchetti, consulente paesaggistico e agronomico e aiuto le persone a fiorire insieme al proprio giardino. Stai ascoltando Giardino Rivelato, da cinque anni il podcast per chi crede fermamente che tutte le persone hanno bisogno di un giardino. Aprirci alla possibilità di non avere tutto sotto controllo, andare oltre l'oltraggio di accettare che il giardino richiede anche una nostra responsabilità: magari può essere l'inizio di una storia bella. Sostieni e finanzia Giardino Rivelato: https://www.patreon.com/francescocecchetti Vieni a trovarmi su giardinorivelato.it

Unisciti alla ribellione su Telegram – Iscriviti alla newsletter – Supportaci su Patreon Qual è il futuro della scrittura sui giochini? Per me non ce n'è, non esiste un futuro, non in senso classico. Io non c'ho più voglia di sottostare per due spicci e per scrivere dei pezzi che tanto non legge nessuno. Si sta meglio a fare i podcast…

Dal 10 luglio il nuovo codice di condotta europeo per l'AI generativa è realtà: obbliga tutti i big (OpenAI, Google, ecc.) a rispettare trasparenza, copyright e sicurezza entro il 2 agosto 2025.L'adesione è volontaria (OpenAI ha già aderito) e chi lo sottoscriverà potrà beneficiare di certezza giuridica e procedure semplificate quando l'AI Act entrerà a pieno regime.Con obblighi di risposta in 14 giorni e storage dati per 10 anni, cambia (forse) tutto per ecosistema e utenti. La compliance ora fa la differenza tra restare nel mercato UE o essere tagliati fuori.Ne parliamo nella nuova puntata di #Compliance&Tech insieme a Giuseppe Vaciago di 42 Law Firm e ad un ospite d'eccezione!

Oggi a Cult Estate: il Mittelfest 2025 inizia sotto la direzione di Giacomo Pedini; Anouk Aspisi e Olivier Dubois firmano Bolzano Danza 2025; Camilla Ronzullo sul libro per giovani "Io sono rabbia" (Salani); l'antropologo Franco La Cecla sulla nuova edizione di "Lo stretto indispensabile" (TCI) di cui è coautore insieme a Piero Zanini; al Kilowatt Festival di Sansepolcro Quotidianacom sullo spettacolo "Marcia, democrazia!"; Raffaele Koehler sul nuovo lavoro degli Slide Pistons "Lato A - Lato B"...

«Non cercavamo un'azienda, cercavamo una casa di campagna, un rifugio per la nostra famiglia. Quando arrivammo su quella collina incolta, ci sembrò un luogo inaccessibile. Io, mio marito e mio suocero salimmo tra la vegetazione fitta, ma poi ci guardammo negli occhi e sentimmo, fortissimo, che quella era casa nostra. Il nostro posto nel mondo.» A raccontarlo è Ria Fonzone, oggi responsabile della comunicazione dell'azienda di famiglia, ma prima ancora testimone e narratrice di un sogno condiviso. Una casa tra i filari, un progetto nato non da un piano industriale ma da una visione familiare: mettere radici. Non solo nel terreno, ma nella terra dell'anima, quella che ti accoglie, ti cambia e ti chiede rispetto.

✨ W33K: il Lunedì che fa la differenza!Un'ora circa per iniziale la settimana con consapevolezza e una marcia in più. I topic di questa puntata:00:02:01 Grok 4: i problemi di allineamento e l'influenza di Elon Musk.00:06:43 L'immigrazione USA (ICE) usa un'app di riconoscimento facciale e impronte digitali.00:09:18 AGCOM condanna Meta a pagare 9 milioni di euro al gruppo Gedi.00:11:35 Indagine irlandese su TikTok per trasferimento di dati degli utenti europei in Cina.00:15:02 Vulnerabilità nel chatbot di reclutamento di McDonald's gestito da Paradox AI.00:17:44 La Spagna affida a Huawei la gestione delle intercettazioni telefoniche nazionali.00:20:37 Nuovo centro di ricerca sull'intelligenza artificiale per comunicare con gli animali.00:22:48 Apple introduce su FaceTime una funzione anti-nudità per proteggere gli utenti.00:26:12 Perplexity lancia Comet, un browser con AI integrata per sfidare il monopolio Google.00:29:37 Il deal tra OpenAI e Windsurf salta, il team passa a Google.00:33:48 La Repubblica Ceca classifica la piattaforma AI DeepSeek come una minaccia nazionale.00:35:46 Le guardie del corpo del premier svedese tracciate tramite l'app Strava.00:39:30 OpenAI sta sviluppando un proprio browser basato su Chromium con AI integrata.00:41:52 Ottenere chiavi di attivazione Windows funzionanti da ChatGPT con un prompt creativo.00:42:48 Indagine penale in Francia contro X per presunta manipolazione algoritmica elettorale.00:46:01 La CEO di X, Linda Yaccarino, annuncia le sue dimissioni dalla guida.00:47:40 Google rilascia MedGemma, un modello AI medico open weight per la ricerca.00:52:27 BlueSky introduce la verifica dell'età nel Regno Unito per l'Online Safety Act.00:54:45 Microsoft risparmia 500 milioni di dollari grazie all'automazione AI nei call center.00:56:38 Aumento dei contenuti pedopornografici generati con intelligenza artificiale secondo l'IWF.00:59:39 La petizione europea ''Stop Killing Games'' raggiunge il milione di firme.01:06:54 Campagna pubblicitaria di Israele su Google contro la relatrice ONU Francesca Albanese.~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

Nella prima lettura continua la storia di Mose: Mosè, lasciato l’Egitto, si ritira nel deserto, dove rimane a servizio di Ietro, sacerdote di Màdian, diventandone anche il genero. Si reca nel deserto fino al monte Oreb a pascolare il gregge del suocero, quando nota una cosa strana: un roveto che arde senza consumarsi. Vuole avvicinarsi per osservare questo fenomeno, ma viene trattenuto da una voce che lo chiama per nome: “Non avvicinarti… lèvati i sandali… poiché il suolo su cui tu stai è una terra santa… Sono il Dio dei tuoi padri… Ho udito il grido degli Israeliti… io stesso ho visto l’oppressione con cui gli Egiziani li tormentano… Ora va! Io ti mando dal faraone. Fa’ uscire il mio popolo dall’Egitto”. Mosè, dinanzi a questa proposta e missione, rimane sconcertato… ma la voce di Dio insiste: “…quando avrai fatto uscire il popolo dall’Egitto, servirete Dio su questo monte”. Ogni vocazione sgomenta e getta nel turbamento… ma come Dio ha dato certezza della riuscita a Mosè, così la dà anche a noi, se sappiamo obbedire alla sua voce. Però il Signore vuole anime docili, pronte a fidarsi di Lui. Gesù, nel breve brano evangelico, ringrazia il Padre perché agli umili di cuore rivela i misteri più profondi del suo essere e della vita. Ognuno di noi ha una chiamata, una vocazione, a realizzare • in noi e in quanti ci sarà concesso di incontrare nella vita • il piano di salvezza del Signore. Nulla avviene a caso, come nulla è avvenuto a caso nella vita di Mosè. Sia il nostro impegno quello di essere di aiuto ai fratelli nel cammino spirituale, con l’esempio della vita e la testimonianza della parola.

Beth GMs for Ellie, Crash, and Io. This episode: The Logistics Trio talk to the guest on their ship and learn there might be a way to stop the plague. Follow this series on… ▶ RSS: https://aaronbsmith.com/cogwheel/tag/gurpswars/podcast ▶ Patreon: https://www.patreon.com/cogwheelgaming ▶ Mastodon: https://is.aaronbsmith.com/@cogwheel MP3 Download: GURPS Wars S1 Ep 69: Preventative Measures Music Used: “Cabin … Continue reading "GURPS Wars S1 Ep 69: Preventative Measures"

IAD Talks - týždenné spravodajstvo. Nemecký výrobca športových a luxusných áut Porsche zaznamenal v prvej polovici roka 2025 pokles globálnych predajov o 6 % a ďalšie čísla potvrdzujú pretrvávajúci trend poklesu dôvery investorov v správnosť smerovania legendárnej značky. Téme sa vo svojom týždňovom komentári z finančných trhov podrobnejšie venuje Adam Záhorský...IAD TALKS, týždenník, IAD Investments, správ. spol., a.s., Malý trh 2/A, 811 08 Bratislava, IČO: 17 330 254, dátum vydania: 14.7.2025, 33/2025, EV 139/23/EPP..*UPOZORNENIE. Tento materiál je marketingovým oznámením. Kompletné znenie upozornenia nájdete na stránke www.iad.sk/marketingoveoznamenia

Un file Excel con i dati di bambini disabili diffuso senza cautele, e impronte digitali usate illecitamente per controllare entrate e uscite. Accade nelle scuole italiane e, per questo, il Garante ha imposto sanzioni fino a 20.000 euro tra marzo e aprile 2023.Con Guido Scorza, del Collegio del Garante per la Privacy, parliamo di errori che possono costare caro agli istituti scolastici. Usare le impronte digitali senza una norma specifica e diffondere dati sulla disabilità può portare a multe salate e procedimenti pesanti.Ma il vero tema è la scuola, quell'istituzione che dovrebbe educare anche ai valori della privacy. E allora la domanda è inevitabile: sta davvero proteggendo la privacy di tuo figlio?E se mancano le risorse perché lo faccia efficacemente, fornirgliele non dovrebbe essere una priorità del Paese?~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

Ezra 3.1-71. Când a venit luna a şaptea, copiii lui Israel erau în cetăţile lor. Atunci poporul s-a strâns ca un singur om la Ierusalim.2. Iosua, fiul lui Ioţadac, cu fraţii săi, preoţii, şi Zorobabel, fiul lui Şealtiel, cu fraţii săi s-au sculat şi au zidit altarul Dumnezeului lui Israel, ca să aducă pe el […]

Giorgio Faletti sapeva fare tutto e lo sapeva fare bene. Dal 26 al 28 settembre a Torino Chora&Will Days, il primo festival di Chora e Will: scopri il programma e come partecipare su days.chorawill.com Fonti: estratti dal documentario “Signor Faletti”, di Michele Truglio e Alessandro Galluzzi del 2025, disponibile sul sito raiplay.it; video “Beppe Grillo - Te La do Io l'America - puntata 1 - 1981” pubblicato sul canale Youtube Gianni Torre il 17 agosto 2019; video “L'Interrogazione di Luca (Scena finale) - NOTTE PRIMA DEGLI ESAMI” pubblicato sul canale Youtube IIF - Italian International Film il 12 giugno 2015; video “E' morto Giorgio Faletti... - Sketch di Vito Catozzo” pubblicato sul canale Youtube Simone Messaggi il 4 luglio 2014; video “Signor tenente ( Sanremo 1994 ) canta Giorgio Faletti” pubblicato sul canale Youtube francesco de leo il 5 febbraio 2012. Learn more about your ad choices. Visit megaphone.fm/adchoices

We're back next week with a new episode, for now we unlock this Patreon bonus episode from 2021, where we induct io Digital Cable and legendary caller Shlomo into the Livecast Hall of Fame. We dive DEEP into the iO digital cable commercial and learn somethings we didn't notice beforeWatch the episode on Youtube for free. Join our Patreon and get a few bonus episode each month, and other behind-the-scenes goodies. More info here.Follow us on: Twitch, Instagram, Facebook, Twitter, Youtube and our Discord Chat. Also don't forget about our Spotify playlist. We also have merch if you're into that kind of sharing. Hosted on Acast. See acast.com/privacy for more information.

Ready for a better commission tracking solution? Don't miss our episode featuring suggestions on tracking your hard-earned commissions.   Register for your FREE RitterIM.com Account   Contact the Agent Survival Guide Podcast! Email us ASGPodcast@Ritterim.com or call 1-717-562-7211 and leave a voicemail.   Resources: AHIP Test Tips and Tricks for Medicare Certification Building the Foundation for Success ft. Roy Snarr Four Reasons Why Ritter Should Be Your FMO Insurance Agency How to Avoid Using Elderspeak Operating From a People-First Mentality ft. Scott Zimmerman The Best Appointment Schedulers for Insurance Agents The Difference Between Medicare & Medicaid: What That Means for Insurance Agents The Ultimate Agent Resource List Pt. 3: Staying Organized What Are Agents Responsible for Under HIPAA?   References: “Agencybloc Commissions Management.” Agencybloc.Com, AgencyBloc, www.agencybloc.com/commissions-management/. Accessed 10 June 2025. “AgencyComp Commissions Tracker.” Agencycomp.Com, AgencyComp, agencycomp.com/. Accessed 10 June 2025. “Commissionly Sales Commission Software.” Commissionly.Io, Commissionly, www.commissionly.io/. Accessed 10 June 2025. “Excel Help & Learning.” Support.Microsoft.Com, Microsoft Support, support.microsoft.com/en-us/excel. Accessed 23 June 2025. “Excel Quick and Simple Charts Tutorial.” YouTube.Com, YouTube, www.youtube.com/watch?v=TfkNkrKMF5c. Accessed 23 June 2025. “How to Create a Chart in Microsoft Excel: Step-by-Step Guide.” wikiHow.Com, wikiHow, 31 Dec. 2024, www.wikihow.com/Create-a-Graph-in-Excel. “How to Create Excel Charts and Graphs.” Blog.Hubspot.Com, HubSpot Blog, blog.hubspot.com/marketing/how-to-build-excel-graph. Accessed 23 June 2025. “Medicare Marketing Guidelines.” CMS.Gov, Centers for Medicare & Medicaid Services, www.cms.gov/medicare/health-drug-plans/managed-care-marketing/medicare-guidelines. Accessed 23 June 2025. “Medicare PRO CRM.” Medicareproapp.Com, Medicare PRO, www.medicareproapp.com/. Accessed 10 June 2025. “Radius Agency Management System.” Radiusbob.Com, Radius, www.radiusbob.com/. Accessed 10 June 2025.   Follow Us on Social! Ritter on Facebook, https://www.facebook.com/RitterIM Instagram, https://www.instagram.com/ritter.insurance.marketing/ LinkedIn, https://www.linkedin.com/company/ritter-insurance-marketing TikTok, https://www.tiktok.com/@ritterim X, https://x.com/RitterIM and YouTube, https://www.youtube.com/user/RitterInsurance       Sarah on LinkedIn, https://www.linkedin.com/in/sjrueppel/ Instagram, https://www.instagram.com/thesarahjrueppel/ and Threads, https://www.threads.net/@thesarahjrueppel    Tina on LinkedIn, https://www.linkedin.com/in/tina-lamoreux-6384b7199/    Not affiliated with or endorsed by Medicare or any government agency. 

Un Superman fuori forma con la faccia di Donald Trump, postato ufficialmente dall'account della Casa Bianca. Un meme virale pubblicato nei giorni scorsi con milioni di visualizzazioni e decine di migliaia di rilanci. Una strategia precisa per deviare l'attenzione dal caso Epstein e sfruttare le controversie sul nuovo film di Superman dipinto come ''immigrato''.Quando meme e politica si mischiano, l'attenzione pubblica si distrae: migliaia di utenti chiedono la lista clienti Epstein, mentre la discussione diventa entertainment. Risultato? Fiducia istituzionale ancora più erosa e meno accountability.Siamo sicuri che usare deepfake e meme sui canali istituzionali sia la scelta giusta per la fiducia nelle istituzioni? Ed è questo lo ''stealing the thunder'' della gestione della Crisi che vogliamo?~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

This week, Hackaday's Elliot Williams and Kristina Panos joined forces to bring you the latest news, mystery sound, and of course, a big bunch of hacks from the previous week. In Hackaday news, the One Hertz Challenge ticks on. You have until Tuesday, August 19th to show us what you've got, so head over to Hackaday.IO and get started now! In other news, we've just wrapped the call for Supercon proposals, so you can probably expect to see tickets for sale fairly soon. On What's That Sound, Kristina actually got this one with some prodding. Congratulations to [$HACKER] who knew exactly what it was and wins a limited edition Hackaday Podcast t-shirt! After that, it's on to the hacks and such, beginning with a ridiculously fast Benchy. We take a look at a bunch of awesome 3D prints a PEZ blaster and a cowbell that rings true. Then we explore chisanbop, which is not actually K-Pop for toddlers, as well as a couple of clocks. Finally, we talk a bit about dithering before taking a look at the top tech of 1985 as shown in Back to the Future (1985). Check out the links below if you want to follow along, and as always, tell us what you think about this episode in the comments!

brianturnershow.com, eastvillageradio.comLOOP - Got To Get It Over - Fade Out (Chapter 22, 1988)CULT FIGURES - Zip Nolan - Live Cedar Club 1980 (Topplers, 2009)THE EDUCATED FOOLS - The Geyser - Tantric Decapitation: 69 Mins of Trichotomy and Liquefaction (NL, 2025)BÉTON ARMÉ - Pendule à L'heure - Demos 2018 (Shoom/Primator Crew, 2018)AVENIR - Petal - Primitive Maxi Trial (Heat Crimes, 2025)HOME SECRETARY - The Singer Said This One Was About Hagfish But Was Actually Thinking About Cigar Sharks - Things! (Chocolate Monk, 2025)TOO MANY ROCK STARS HATE EACH OTHERTUNE ZITOUNE - Haragarider - Ouais Enfin Voilà Quoi (La Face Cachee, 2025)MARC RILEY - Wanted Man - V/A: Til Things Are Brighter: A Tribute To Johnny Cash (Red Rhino, 1988)SACRED LODGE -  WWa Ke Wa Wa Yi (Feat. Sara Persico) - Ambam (Avor Terror Corps, 2025)XEROXHEAD - Batterie Gelée - I/O (cs, Un Poco Fría, 2025)AUFGEHOBEN - Anno Fauve - Anno Fauve (Riot Season, 2004)GREY DATURAS - Beyond and into the Ultimate - Return To Disruption (Neurot Recordings, 2008)NAOKI ZUSHI - Yearning of Flowers - III (2005, re: World of Echo, 2025)SIR RICHARD BISHOP - They Shall Take up Serpents - Hillbilly Ragas (Drag City, 2025)CCR DOG - Fortunate DogSAVOY HAVANA BAND - I'm Gonna Bring a Watermelon to My Girl Tonight - V/A: Songs The Bonzo Dog Band Taught Us (Voiceprint, 2009)ATMO - Zeitfenster - Brechen (cs, Latenz, 2025)BRUCE SINGS ABOUT DADDY A LOTMENTOCOME - 12 - Mentocome (1992, re: Amok Age, 2025)A SET FOR JOHN WHITSON:BLUES CONTROL - Frankie's Problem - Blues Control (Holy Mountain, 2007)ALEJANDRO MEDINA Y LA PASADA - Un Estado Natural - Alejandro Medina Y La Pasada (1974, re: Mondo Svart, 2020)THE ROLLING STONES - Happy - Will Keith Wake Up In Time For the Afternoon Show in Perth Australa 24/2/1973?? (Human Riff)AINOTAMENISHIS - I Don't Smoke It - Live '418 (Holy Mountain, 2007)ONNA - Were You To Become a Mother - Onna (Holy Mountain, 2009)LES RALLIZES DÉNUDÉS - Reapers of the Night - Baus '93 (Temporal Drift, 2023)

A pill of grains grown in music. Credits :  “La guerra di Piero” by F. De André (1964)  -  “Pensieri e parole” by L. Battisti / G. Rapetti (1971)  -  “Io canto” by R. Cocciante / M. Luberti (1979)Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/pillole-di-italiano--4214375/support.

Ellie GMs for Beth, Crash, & Io as they play student's enrolled in the other Mo's other super-powered school. It's time for mini-golf! Follow this series (of one-shots) on… ▶One-Shots RSS Feed: https://aaronbsmith.com/cogwheel/tag/one-shot/feed/ ▶Patreon: https://www.patreon.com/cogwheelgaming ▶Mastodon: https://is.aaronbsmith.com/@cogwheel MP3 Download: One-Shot: Mo's School for the Delinquent And Disturbed (Cypher System) Music Used: Bubble Machine by Drozerix … Continue reading "One-Shot: Mo's School for the Delinquent And Disturbed (Cypher System)"

Get this full episode and support the pod! ⁠Join our Patreon ⁠for $5 a month for full episodes, bonus eps and exclusive premium content!⁠Join the Discord community⁠Dive into our discord channel to connect with fellow fans, discuss your favorite episodes, and meet the hosts of the show!It's an all new episode ft. our very funny and good friend of the pod Kyle Bethea and for the first time the VERY funny Sage Huston! We chat'n'prov about travel, tables for dogs, insta- cancels and more!Local to Chicago?Follow Kyle on social media to see what he's up to on a weekly basis!See Sage as part of Creamboy, Saturdays at iO and Little Hero's Sunday at Logan Square ImprovHosts: ⁠Damian Anaya⁠, ⁠Tim Lyons⁠, and ⁠Dan White⁠

Your strengths aren't just what you're good at—they're your career compass. When you ignore your signature strengths, even great opportunities become draining. Discover how one IO psychologist used her strengths to break free from the "great opportunity trap" and find work that truly energizes her.   What you'll learn Why your signature strengths should guide your career experiments and decisions How to get valuable feedback from friends and family about your natural talents The difference between skills you can do versus strengths that energize you   Our book, Happen To Your Career: An Unconventional Approach To Career Change and Meaningful Work, is now available on audiobook! Visit  happentoyourcareer.com/audible to order it now! Visit happentoyourcareer.com/book for more information or buy the print or ebook here! Want to chat with our team about your unique situation? Schedule a conversation   Free Resources What career fits you? Join our free 8 Day Mini Course to figure it out! Career Change Guide - Learn how high-performers discover their ideal career and find meaningful, well-paid work without starting over.   Related Episodes Discover Your Strengths to Find Your Ideal Career (Spotify / Apple Podcasts) Should I Quit My Job? How to Know It's Time (Spotify / Apple Podcasts)

Hon är Italiens första kvinnliga premiärminister, en fantasyälskande populist som har ifrågasatts för sina kopplingar till landets mörka historia. Nya avsnitt från P3 ID hittar du först i Sveriges Radio Play. ”Io sono Giorgia, sono una donna, sono una madre!” – ”Jag är Giorgia, jag är kvinna, jag är mamma, jag är italienare, jag är kristen. Det kan de aldrig ta ifrån mig!”Orden ekar ut över en enorm folkmassa på Piazza San Giovanni i Rom hösten 2019. Vid talarpodiet står en kort kvinna med blont hår, ledigt klädd i mörka byxor och en fladdrig ljusgrå blus.Trots att hon är flankerad av flera politiska tungviktare så är det Giorgia Meloni, partiledare för Italiens bröder, som stjäl showen den här dagen. Hennes eldiga ord blir det politiska manifest som kommer att bära Meloni och hennes parti till valseger några år senare.Giorgia Melonis politiska resa inleds i början på 90-talet, när hon som 15-åring ringer på dörren till Fronte della Gioventù, det politiska partiet Movimento Sociale Italianos ungdomsförbund.Det är ett parti som grundades av den fascistiske diktatorn Benito Mussolinis anhängare, och som vid den tiden befinner sig på utkanten av det italienska etablissemanget på grund av de historiska banden till en tid som präglades av skräck och våld.P3 ID om Giorgia Meloni följer hennes utveckling från blyg tonåring med en gnagande känsla av att något är fel i det italienska samhället, till retorisk pitbull som inte räds någon motståndare på den politiska arenan.I avsnittet medverkar Eskil Fagerström, journalist på Sydsvenskan och författare till flera böcker om det moderna Italien, Giulia Kappelin Cingolani, journalist baserad i Italien, och Filip Jacobson, utrikesreporter på TV4.Klippen i avsnittet är hämtade från Rai, Right Side Broadcasting Network, Giorgia Melonis Facebooksida, Fratelli d'Italias Youtubekanal, Wine News, Diario AS, VOA Africa, Vista Agenzia Televisiva Nazionale, Vita husets Youtubekanal, British Pathé, La7 Attualità.

Beth GMs for Ellie, Crash, and Io. This episode: The Logistics Trio ascend to the other spaceship and look for a missing Dark Lord. Follow this series on… ▶ RSS: https://aaronbsmith.com/cogwheel/tag/gurpswars/podcast ▶ Patreon: https://www.patreon.com/cogwheelgaming ▶ Mastodon: https://is.aaronbsmith.com/@cogwheel MP3 Download: GURPS Wars S1 Ep 68: Bespoke Spokes Music Used: “Cabin Fever!” by Drozerix is licensed as … Continue reading "GURPS Wars S1 Ep 68: Bespoke Spokes"

- Premere il tasto PLAY per ascoltare la catechesi del giorno -+ Dal Vangelo secondo Matteo +In quel tempo, Gesù, vide un uomo, chiamato Matteo, seduto al banco delle imposte, e gli disse: «Seguimi». Ed egli si alzò e lo seguì.Mentre sedeva a tavola nella casa, sopraggiunsero molti pubblicani e peccatori e se ne stavano a tavola con Gesù e con i suoi discepoli. Vedendo ciò, i farisei dicevano ai suoi discepoli: «Come mai il vostro maestro mangia insieme ai pubblicani e ai peccatori?».Udito questo, disse: «Non sono i sani che hanno bisogno del medico, ma i malati. Andate a imparare che cosa vuol dire: “Misericordia io voglio e non sacrifici”. Io non sono venuto infatti a chiamare i giusti, ma i peccatori».Parola del Signore.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Dr. Ari Wes, Partner at Peninsula Plastic Surgery and CEO and Cofounder of Orchid Surgical, about clinical surgery video production. Chapters 00:00 Intro 01:46 Interview Preview 02:16 No Chest-Open Heart Transplant 05:07 NSCLC Time to Surgery 07:55 Impact of Preop Invasive Nodal Staging 11:04 Air Space Spread Impacts Adenocarcinoma 14:26 Intrapericard Pneum w Broncho & Flap 16:42 Ross Procedure Unveiled 21:16 Radial Artery Harvesting Podcast 23:32 Dr. Wes Interview, Video Production 46:06 Cardiac Surgical Arrest Series 46:52 Closing They discuss the value of starting with the right camera, the impact of field of view, head-mounted cameras vs. stationary cameras, and the importance of capturing the surgeon's perspective. Additionally, they explore the educational benefits of recording surgeries, the criteria for selecting an ideal storage solution for recordings, and the future of clinical surgery videos.   Joel also highlights recent JANS articles on first fully robotic heart transplant in the US performed without opening the patient's chest, defining the optimal diagnosis-to-resection interval to reduce mortality in early-stage non-small cell lung cancer, concurrent spread through air spaces in dominant tumors impacts prognosis in synchronous multiple primary lung adenocarcinoma, and the impact of preoperative invasive nodal staging on unexpected mediastinal upstaging in early-stage non-small cell lung cancer.  In addition, Joel explores a robot-assisted intrapericardial pneumonectomy with bronchoplasty and thymic flap post neoadjuvant chemo/IO, insights into various techniques and modifications for the Ross procedure, and an episode of The Atrium podcast featuring host Dr. Alice Copperwheat speaking with Dr. Faisal Bakaeen from the Cleveland Clinic on radial artery harvesting. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) First Fully Robotic Heart Transplant in the US Performed Without Opening Patient's Chest  2.) Time to Surgery in Early-Stage Non-Small Cell Lung Cancer: Defining the Optimal Diagnosis-to-Resection Interval to Reduce Mortality  3.) Concurrent Spread Through Air Spaces in Dominant Tumors Impacts Prognosis in Synchronous Multiple Primary Lung Adenocarcinoma   4.) The Impact of Preoperative Invasive Nodal Staging on Unexpected Mediastinal Upstaging in Early-Stage Non-small Cell Lung Cancer   CTSNET Content Mentioned  1.) Robot-Assisted Intrapericardial Pneumonectomy With Bronchoplasty and Thymic Flap Post Neoadjuvant Chemo/IO  2.) The Ross Procedure Unveiled: Insights into Various Techniques and Modifications   3.) The Atrium: Radial Artery Harvesting   Other Items Mentioned  1.) Cardiac Surgical Arrest—An International Conversation, Part 2  2.) Career Center   3.) CTSNet Events Calendar Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Beth GMs for Ellie, Crash, and Io. This episode: The Logistics Trio continue to explore, but are forced to deal with problems previously locked away. Follow this series on… ▶ RSS: https://aaronbsmith.com/cogwheel/tag/gurpswars/podcast ▶ Patreon: https://www.patreon.com/cogwheelgaming ▶ Mastodon: https://is.aaronbsmith.com/@cogwheel MP3 Download: GURPS Wars S1 Ep 67: Womp Rat in Corner Pocket Music Used: “Cabin Fever!” by … Continue reading "GURPS Wars S1 Ep 67: Womp Rat in Corner Pocket"

Federica Falzea ha 43 anni, vive a Milano ma è nata e cresciuta a Lecce in una famiglia dove l'istruzione è sempre stata il vero motore di riscatto sociale. Figlia di due medici, Federica sceglie un approccio più olistico alla cura: va a studiare osteopatia a Milano, trovando alloggio presso una congregazione di suore, dove per la prima volta entra in contatto con la vita religiosa. Dopo quattro anni di studio, la svolta. Decide di lasciare la scuola per entrare in convento, dove trascorre nove anni studiando Psicologia Giovanile e Teologia. Col tempo, però, la spinta iniziale inizia ad affievolirsi e Federica decide di lasciare la vita religiosa per riprendere gli studi di osteopatia. In tre anni conclude la scuola, apre uno studio, si sposa e ha due figli.Tutto procede bene fino al 2022, quando le viene diagnosticato un tumore al peritoneo. Durante l'intervento le vengono asportati anche utero e ovaie e, dopo l'operazione, cominciano sintomi molto potenti: confusione, sbalzi d'umore, sudorazione e insonnia, inizialmente attribuiti all'intervento.Nella casa di cura dove è stata operata, nessuno la informa che la rimozione degli organi riproduttivi avrebbe causato una menopausa chirurgica precoce. Solo in seguito, grazie alla sua ginecologa, arriva la diagnosi corretta e l'inizio della terapia ormonale sostitutiva, la TOS. Federica sta meglio, ma si ritrova ad affrontare un nuovo ostacolo: i costi.La terapia, infatti, è tutta a carico suo. Tra farmaci, pomate specifiche e fisioterapia riabilitativa legata ai sintomi della menopausa, la spesa arriva facilmente a superare i 3.000 euro all'anno. Una cifra significativa, soprattutto se si considera che molte di queste cure non sono un “di più”, ma un'esigenza per continuare a vivere bene. I costi della menopausa non si fermano però alle terapie: si riflettono anche sul lavoro. Le donne affrontano questo passaggio fisiologico nel momento di massima responsabilità e rendimento professionale. Secondo uno studio anglosassone, ogni anno le donne in menopausa si assentano dal lavoro per una media di 24 ore, causando una perdita economica stimata in 15 milioni di euro. E se lavori in proprio, come Federica, il prezzo si misura in termini di mancato guadagno: «Io, da agosto del 2022, dopo circa cinque mesi, ho ripreso a lavorare. Cinque mesi senza alcuna entrata, senza alcun guadagno».Così, per contrastare anni di invisibilità e disinformazione, Federica e un'amica, Silvia, decidono di dare vita a MenoP: un progetto che vuole rompere il tabù attorno alla menopausa e dare finalmente voce a un'esperienza femminile ancora troppo spesso ignorata. Insieme organizzano focus group e incontri nelle aziende, portando formazione e consapevolezza dove ancora mancano strumenti e parole: «Cerchiamo di offrire una narrazione della menopausa diversa da quella che ci viene solitamente proposta, una narrazione in cui possiamo davvero riconoscerci e sentirci coinvolte».

Marco Bonfanti"Appunti contadini"Edizioni Clichywww.edizioniclichy.it«Non posso più muovermi di qua. Come vi diceva, non c'ho macchina e c'ho pure il bastone. Eppure ogni jorno vedo il mare dal mio balcone e mi sembra di viaggiare. È qui davanti a me, a pochi metri di lontananza. Ogni mattina lo guardo per una o due ore, da solo, nel silenzio. Quando era giovane volevo scappare di qua, ma mo' non cambierei mai questo posto per un altro. Ve lo giuro…»Gli ultimi cento anni della storia d'Italia raccontati dallo sguardo e nelle parole di un contadino calabrese.«Mi chiamo Michele Naccari e sono nato di Tropea tantissimi anni fa, che manco mi ricordo più quanti. E la mia vita non è stata tranquilla come voi adesso. Allora era tutto differente. Adesso voi girate, facete e guadagnate qualcosa. Io ho dovuto sudarla la vita mia».A raccontare in prima persona questa «vita sua», lunga e sfiancante fin da quando era un ninno, è un contadino calabrese, semi-analfabeta, ormai vecchio, senza quasi più forze ma con ancora un'indomabile voglia di lottare, di aggrapparsi agli ultimi istanti di un'esistenza trascorsa tra fame e povertà, spinto dalla forza di volontà, «perché io la testa non l'abbasso davanti a nessuno». Nelle sue parole sgangherate, al tempo stesso così incomprensibili e chiare, nella sua lingua imprevedibile eppure vitale, tutto si fa ricordo, nostalgia. Nel suo eloquio sghembo scorre davanti a noi un secolo di storia d'Italia, con le sue grandezze e le sue miserie, le sue speranze e le sue sconfitte: gli albori del Novecento, il fascismo, la guerra, l'emigrazione, la ricerca di un lavoro che non c'è, il mondo che cambia sotto gli occhi, la vita e le persone che cambiano con lui, fino ai giorni nostri, una nuova epoca tanto difficile da capire quanto impossibile da fermare.Una storia narrata dalla parte degli ultimi, dei dimenticati, degli sconfitti, che dipinge chi siamo e chi siamo stati, che ci ricorda la nostra fragile e ostinata umanità. Un secolo di storia italiana raccontato attraverso gli occhi, le memorie e le parole sbilenche di chi l'ha attraversata restandone di lato, là dove spesso la storia non guarda, un vecchio contadino che ha mescolato la sua esistenza con la terra e che si racconta tutto d'un fiato, come d'un fiato scorrono le vite con la loro inarrestabile, travolgente potenza.Marco Bonfanti nasce a Milano nell'agosto del 1980. Dopo aver realizzato due pluripremiati cortometraggi, Le Parole di Stockhausen nel 2008 e Ordalìa (dentro di me) nel 2009, il 1° ottobre del 2011 porta un gregge di oltre settecento pecore in piazza del Duomo a Milano: la notizia fa il giro del mondo e viene ripresa dai principali media. Si tratta di una scena del suo lungometraggio d'esordio, L'Ultimo Pastore, un film che diventa rapidamente un caso nazionale e internazionale, invitato in oltre centoventi festival nel mondo, fra cui il Sundance (Slamdance), Tokyo, Torino, Dubai, Kerala, Transilvania, Bangkok, Sidney e Seattle, e vincitore di numerosi premi. Nel 2014 realizza Tubiolo e la Luna, episodio del film collettivo 9×10 Novanta, presentato alla 71esima Mostra d'Arte Cinematografica di Venezia, che si aggiudica un Nastro D'Argento speciale. Nel 2016 dirige Bozzetto non troppo, documentario sul celebre animatore Bruno Bozzetto, in concorso alla 73esima Mostra d'Arte Cinematografica di Venezia nella sezione Venice Classics, invitato all'Annecy Animation International Film Festival e in cinquina ai Nastri D'Argento come miglior film documentario. Nel 2019 realizza il lungometraggio L'Uomo senza Gravità, interpretato – fra gli altri – da Elio Germano, Michela Cescon ed Elena Cotta. Il film è invitato alla Festa del Cinema di Roma e allo Shanghai International Film Festival, ed è scelto da Netflix come Film Original. Nel 2024 lavora a un documentario sullo Stato della Città del Vaticano sotto il pontificato di Papa Francesco, di prossima uscita. Appunti contadini è il suo primo romanzo.IL POSTO DELLE PAROLEascoltare fa pensarewww.ilpostodelleparole.itDiventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.

(00:00:00) "Festeggiamo i 10 anni di Apple Music" (00:00:12) Ciao Paolo Bitta (00:00:38) In attesa delle vere novità di Samsung e Google (00:02:14) Sviluppi in Casa Apple (00:03:06) I rumors su Apple (00:03:45) Arriva il MacBook con l'A18 Pro? (00:05:17) Dieci anni di Apple Music (00:07:19) Apple Music vs Spotify (00:08:49) Apple Music: Integrazione e Funzionalità (00:13:25) La storia della Musica (00:15:41) Esperienze personali con Apple Music (00:19:52) Apple Music e l'ecosistema (00:23:46) Vent'anni di Apple Podcast (00:26:41) L'evoluzione dei Podcast (00:29:33) Apple TV+ (00:34:11) Apple Fitness + (00:36:40) Dov'è Apple News? Oggi celebriamo due compleanni importanti: i 10 anni di Apple Music e i 20 anni di Apple Podcast. Un episodio nostalgico e riflessivo sui servizi Apple, dall'eredità di iTunes Store all'evoluzione dello streaming musicale, dall'integrazione ecosistemica alle chicche come iTunes Match e Replay.Con voi ripercorro la mia esperienza personale con Apple Music dal day one, analizzo l'evoluzione dei podcast da nicchia tech a fenomeno mainstream, e faccio il punto sugli altri servizi di Cupertino: Apple TV+, Arcade, Fitness+ e il sogno (ancora irrealizzato) di Apple News+ in Italia.La puntata di IO&TEch in cui ho parlato del potenziale Apple RingLa puntata del SaggioPodcast in cui sono stato ospitesVisita Digiteee e scopri tutte le notizie sulla tecnologiaSegui Digiteee su TikTokDimmi la tua su Twitter, su Threads, su Telegram, su Mastodon, su BlueSky o su Instagram.Mail jacoporeale@yahoo.it Scopri dove ascoltare il podcast e lascia una recensione su Apple Podcast o Spotify.Ascolta An iPad guy su YouTube Podcast.Supporta il podcast

Help MuggleCast grow! Become a MuggleCast Member and get great benefits like Bonus MuggleCast! Patreon.com/MuggleCast  Grab official merch! MuggleCastMerch.com Pick up overstock merch from years past, including our 19th Anniversary Shirt! MuggleMillennial.Etsy.com On this week's episode, break out the scantrons and No. 2 pencils because Harry, Ron and Hermione are finally sitting their O.W.L.s. Join Andrew, Eric, Micah, Laura and Slug Club member Stacy for the stress-inducing conclusion to Harry's fifth year at Hogwarts. And if exams weren't enough, Hagrid's been sacked and Voldemort has Sirius! Welcome Slug Club member, Stacy! Chapter-by-Chapter continues with Harry Potter and the Order of the Phoenix, Chapter 31: O.W.L.s. Our Time Turner segment takes us back to Episode 468 of MuggleCast, titled “Rubeus Hagrid's Punch Out.”  Ron cannot stop talking about his big Quidditch win! Did we ever have a friend who just wouldn't shut it about a big accomplishment? Magical Moment: Ron reminds Harry of his father James After learning about Grawp, Ron raises a fantastic point: “Have we ever come off better for mixing with one of Hagrid's monster mates?” How do the O.W.L. exams reflect real-world academic pressures? Draco drops some real world knowledge: "It's not what you know, but who you know!" Why do the students have to wait until July for their scores? Shouldn't magic allow for instant results? Wingardium Leviosa, Polyjuice Potion & Patronuses! During Harry's O.W.L.s, we get several throwbacks to the first three books! Speaking of Patronuses, is Professor Tofty playing favorites? Does he offer the other students bonus points? What does the nighttime ambush of Hagrid suggest about the Ministry's tactics? Sirius Problem: Voldemort has Harry's godfather in the Department of Mysteries! What would Harry's post-exam life look like if he didn't have a Dark Lord inside of his head? The hosts share which O.W.L. they would most like to sit! Harry overhears Professor Marchbanks tell Professor Umbridge that Dumbledore “Did things with a wand I'd never seen before!” In our Lynx Line segment for the week, we ask our Patrons what kind of things do you imagine Dumbledore doing to impress the examiners? Quizzitch: Harry struggles to name all of the moons of Jupiter for his Astronomy O.W.L. WHICH of the FOLLOWING is NOT one of Jupiter's moons? Io, Metis, Europa, Ganymede, Calypso, Themisto, Pandia, and S/2003 J 2. Join in on the fun! Tilda Swinton? Peter O'Toole? James McAvoy? Michael Cera!? On this week's Bonus MuggleCast, we discuss the actors who turned down Harry Potter roles!   Learn more about your ad choices. Visit megaphone.fm/adchoices

The AI drama is full tilt!↳ Meta and OpenAI have all but declared a war on top tech talent. ↳ Google released a free AI coding tool that will likely make huge cuts into Claude's customer base. ↳ Salesforce says AI is doing their own jobs for them. And that's just the tip of the AI iceberg y'all. Don't waste hours a day trying to keep up with AI. Instead, join us on Mondays as we bring you the AI News That Matters.Newsletter: Sign up for our free daily newsletterMore on this Episode: Episode PageJoin the discussion: Thoughts on this? Join the convo.Upcoming Episodes: Check out the upcoming Everyday AI Livestream lineupWebsite: YourEverydayAI.comEmail The Show: info@youreverydayai.comConnect with Jordan on LinkedInTopics Covered in This Episode:AI Talent War: Meta vs. OpenAIAI Firms and Copyright Lawsuits UpdateOpenAI Trademark Battle with IOEleven Labs' New Voice AI LaunchUS Senate AI Regulation DealAnthropic's Claude Platform Features UpdateSalesforce's AI Workload IntegrationGoogle Gemini CLI Free Coding ToolMeta's Aggressive AI Talent RecruitmentOpenAI's Strategy to Retain ResearchersTimestamps:00:00 "AI News: Weekly and Daily Updates"03:12 AI Copyright Lawsuits: Early Rulings09:18 OpenAI-IO Trademark Dispute Unveiled12:23 Futile Lawsuit Against New Gadget14:21 "11 AI: Voice-Activated Task Assistant"17:37 "AI Strategy and Education Solutions"21:54 Federal AI Funding and State Regulation25:05 States Must Forego AI Regulation28:18 Anthropic Updates Claude with Artifacts31:23 Claude vs. Google Usage Limits37:17 Google Disrupts Coding with Free Tool40:17 Meta's AI Talent and Business Strategy44:20 OpenAI Responds to Meta Poaching45:49 AI Developments: LLaMA and Grok Updates49:14 OpenAI Faces Lawsuit Over IOKeywords:AI talent war, Meta, OpenAI, Federal judges ruling, California federal judges, Copyrighted books, Anthropic, Meta's legal win, Sarah Silverman, US Supreme Court, Intellectual property rights, New York Times vs OpenAI, Disney lawsuit, Universal lawsuit, Midjourney, State AI regulation, Federal funding, US Senate, Ten-year ban, Five-year ban, AI infrastructure, Federal AI funds, Sam Altman, IO hardware startup, Trademark battle, Hardware device, Eleven Labs, 11 AI, Voice assistant, Voice command execution, MCP, Salesforce, Marc Benioff, AI workload, AI agents, Anthropic Claude update, Artifacts feature, Artifact embedding, Salesforce customer service, Command line interface, Gemini CLI, Gemini 2.5 pro, Coding tools, Desktop coding agent, Meta poaching, Superintelligence lab, AI researchers, Meta's aggressive recruitment, Llama four, Llama 4.5, Microsoft, Anthropic, Google Gemini scheduled tasks, GoogleSend Everyday AI and Jordan a text message. (We can't reply back unless you leave contact info) Ready for ROI on GenAI? Go to youreverydayai.com/partner

This week, we're cutting to the chase on the latest in AI, from legal battles to the impact on our brains.Here's what's in store:AI News: June 19-25 – A quick hit on the week's key headlines. 4/10A Call for Guests: If you want to be on the show, stand out! Learn how to pitch effectively and avoid the "AI-generated slop" pile.Midjourney's New Video Tools: Turn your still images into dynamic videos with new animation modes, motion intensity control, video extensions, and even external image support.The OpenAI vs. Google "IO" Showdown: Dive into the bombshell lawsuit surrounding OpenAI's $6.5 billion acquisition of Jony Ive's "Altman IO" and the trademark infringement battle with Google-backed "the original IO." Accusations include secret tracking, product purchases, and alleged threats from Sam Altman to force a name change.ChatGPT's App Store Dominance: ChatGPT's downloads nearly rival the combined might of TikTok, Facebook, Instagram, and X.Are LLMs Making Us Dumber? We'll tackle the MIT research linking ChatGPT use to cognitive decline. Plus, we'll discuss how readily available answers affect our critical thinking and the long-term implications for the next generation. As Balaji says, "AI doesn't do it end-to-end. It does it middle-to-middle. The new bottlenecks are prompting and verifying."

Meet the incredible Rebecca Sohn! She is originally a New Jersey girl but has had so many adventures since leaving home at age 18. She describes her father and how he fostered her creativity by building a stage in their basement for her to give dancing performances. Her dad involved the whole family in co-writing a play, which was basically improvised and was produced at two local schools. Her passion and love was ballet until age 16 when she tragically "grew out of a dancer's body" and gave up her dream of being the Prima Ballerina of the World. She remembers her high school English teacher, Ms Bartow, who nurtured her students' artistic sides. At 18 she moved to Boston and recalled seeing an Improv Touring Company Show, but didn't walk away thinking “This is what I want to do.” A few years later she moved to the Bay Area of California and was able to attend school and knew she wanted to be an actor. But the acting classes were full so she enrolled in an improv class, with the thought it would help her acting. While in SF she met Charna Halpern of the IO and was invited to Chicago and the rest was history! It was Charna who persuaded her to date Rebecca's (now) husband, Rich Sohn! To learn more you'll have to listen to the podcast. You can find out even more about Rebecca at her website www.rebeccasohn.com

A massive repository of information about OpenAI and Altman just dropped, our take on the man who tried to marry his AI assistant, your calls, and a lot more.

Automakers, tech giants, and others push back against Trump's proposed 25% chip tariff.It's reported that the US strikes on Iran's nuclear facilities in Fordow and Natanz actually only set Iran's nuclear program back about 3-6 months. Sam Altman leaks emails between him and IYO founder Jason Rugolo ahead of their legal battle over OpenAI's IO.And we got a special funding announcement from a company creating new digital minds.Featured Guests: Rob Biederman, Managing Partner, Asymmetric Capital Partners and Dara Ladjevardian, Co-founder and CEO, DelphiDOWNLOAD PUBLIC: ⁠https://public.com/ventureInvest in everything—stocks, options, bonds, crypto. You can even earn some of the highest yields in the industry—like the 7% or higher yield you can lock in with a Bond Account. Public is a FINRA-registered, SIPC-insured platform that takes your investments as seriously as you do. Fund your account in five minutes or less at ⁠⁠(https://public.com/venture?utm_source...) and get up to $10,000 when you transfer your old portfolio.All investing involves the risk of loss, including loss of principal. Brokerage services for US-listed, registered securities, options and bonds in a self-directed account are offered by Public Investing, Inc., member FINRA & SIPC. Public Investing offers a High-Yield Cash Account where funds from this account are automatically deposited into partner banks where they earn interest and are eligible for FDIC insurance; Public Investing is not a bank. Cryptocurrency trading services are offered by Bakkt Crypto Solutions, LLC (NMLS ID 1890144), which is licensed to engage in virtual currency business activity by the NYSDFS. Cryptocurrency is highly speculative, involves a high degree of risk, and has the potential for loss of the entire amount of an investment. Cryptocurrency holdings are not protected by the FDIC or SIPC. A Bond Account is a self-directed brokerage account with Public Investing, member FINRA/SIPC. Deposits into this account are used to purchase 10 investment-grade and high-yield bonds. The 7%+ yield is the average, annualized yield to worst (YTW) across all ten bonds in the Bond Account, before fees, as of 5/15/2025. A bond's yield is a function of its market price, which can fluctuate; therefore, a bond's YTW is not “locked in” until the bond is purchased, and your yield at time of purchase may be different from the yield shown here. The “locked in” YTW is not guaranteed; you may receive less than the YTW of the bonds in the Bond Account if you sell any of the bonds before maturity or if the issuer defaults on the bond. Public Investing charges a markup on each bond trade. See our Fee Schedule (https://public.com/disclosures/fee-sc...)*Terms and Conditions (https://help.public.com/en/articles/6...) apply.

Dr. Vamsi Velcheti and Dr. Nate Pennell discuss novel treatment approaches in small cell and non-small cell lung cancer that were featured at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I'm Dr. Vamsi Velcheti, your guest host of the ASCO Daily News Podcast. I'm a professor of medicine and chief of hematology and oncology at the Mayo Clinic in Jacksonville, Florida. The 2025 ASCO Annual Meeting featured some exciting advancements in small cell lung cancer, targeted therapies for non-small cell lung cancer, and other novel [treatment] approaches. Today, I'm delighted to be joined by Dr. Nate Pennell to discuss some of the key abstracts that are advancing the lung cancer field. Dr. Pennell is the co-director of the Cleveland Clinic Lung Cancer Program and also the vice chair of clinical research at the Taussig Cancer Institute. Our full disclosures are available in the transcript of this episode. Nate, it's great to have you back on the podcast. Thanks so much for being here. Dr. Nate Pennell: Thanks, Vamsi. Always a pleasure. Dr. Vamsi Velcheti: Let's get started, and I think the first abstract that really caught my attention was Abstract 8516, “The Randomized Trial of Relevance of Time of Day of Immunotherapy for Progression-Free and Overall Survival in Patients With Non-Small Cell Lung Cancer.” What are your thoughts about this, Nate? Dr. Nate Pennell: I agree. I thought this was one of the most discussed abstracts, certainly in the lung cancer session, but I think even outside of lung cancer, it got some discussion. So, just to put this in perspective, there have been a number of publications that have all been remarkably consistent, and not just in lung cancer but across multiple cancer types, that immunotherapy, immune checkpoint inhibitors, are commonly used. And all of them have suggested, when looking at retrospective cohorts, that patients who receive immune checkpoint inhibitors earlier in the day – so in the morning or before the early afternoon – for whatever reason, appear to have better outcomes than those who get it later in the day, and this has been repeated. And I think many people just sort of assumed that this was some sort of strange association and that there was something fundamentally different from a prognostic standpoint in people who came in in the morning to get their treatment versus those who came later in the afternoon, and that was probably the explanation. The authors of this randomized trial actually decided to test this concept. And so, about 210 patients with previously untreated advanced non-small cell lung cancer were randomly assigned to get chemo and immune checkpoint inhibitor – either pembrolizumab or sintilimab – and half of them were randomly assigned to get the treatment before 3 PM in the afternoon, and half of them were assigned to get it after 3 PM in the afternoon. And it almost completely recapitulated what was seen in the retrospective cohorts. So, the median progression-free survival in those who got earlier treatment was 13.2 months versus only 6.5 months in those who got it later in the day. So, really enormous difference with a hazard ratio of 0.43, which was statistically significant. And perhaps even more striking, the median overall survival was not reached in the early group versus 17.8 months in the late group with a hazard ratio of 0.43, also highly statistically significant. Even the response rate was 20% higher in the early patients; 75% response rate compared to 56% in the late-time-of-day patients. So very consistent across all measures of efficacy with pretty good matched characteristics across the different groups. And so, I have to tell you, I don't know what to make of this. I certainly was a skeptic about the retrospective series, but now we have a prospective randomized trial that shows essentially the same thing. So, maybe there is a difference between getting treated in the morning, although I have yet to hear someone give a very good mechanistic explanation as to why this would be. What were your thoughts on this? Dr. Vamsi Velcheti: It's indeed fascinating, Nate, and I actually think this was a very interesting abstract. Really, I was caught off guard looking at the data. I mean, if it were a drug, we would be so excited, right? I mean, with those kind of survival benefits. I don't know. I think circadian rhythm probably has something to do with it, like different cytokine profiles at the time of administration. I mean, who knows? But I think it's a randomized trial, and I think I would expect to see a mad rush for treatment appointments early in the morning given this, and at least I want my patients to come in first thing in the morning. It'll be interesting to see. Dr. Nate Pennell: It's important to point out that in this study, everyone got chemo and immunotherapy. And, at least in our cancer center, most patients who are getting platinum-doublet chemotherapy and immunotherapy actually do get treated earlier in the day already, just because of the length of the infusion appointment that's needed. So it really is oftentimes people getting single-agent immunotherapy who are often getting the later, shorter visits. But if you have a choice, I think it would be very reasonable to have people treated earlier in the day. And I do think most of the impressions that I got from people about this is that they would like to see it reproduced but certainly well worth further investigation. And I personally would like to see more investigation into what the rationale would be for this because I still can't quite figure out, yes, if you got it at, say, you know, 5 PM, that's later in the day and I can understand that maybe your immune system is somewhat less receptive at that point than it would be in the morning. But because these checkpoint inhibitors have such long half-lives, it's still in your system the next morning when your immune system is supposedly more receptive. So I don't quite understand why that would be the case. Well, let's move on to the next study. I would like to hear your thoughts on Abstract 8515, “Plasma-Guided, Adaptive First-Line Chemoimmunotherapy for Non-Small Cell Lung Cancer.” Dr. Vamsi Velcheti: Yeah, this was another abstract that seems to be really interesting in my opinion. I think there's kind of a lot of emphasis lately on ctDNA and MRD-based assays to monitor disease. In the lung cancer space, we haven't had a lot of clinical trials looking at this prospectively, and this was one of those pilot studies where they looked at circulating free DNA (cfDNA)-based response-adaptive strategy for frontline patients who are PD-L1 positive. So, patients started with pembrolizumab monotherapy, and based on plasma molecular response after 2 cycles, those patients without response received early treatment intensification with a platinum doublet. So the approach essentially was to reduce the chemotherapy exposure in patients who respond to immunotherapy. And only about 17.5% of the patients on the trial received chemotherapy based on lack of molecular response. So, in this trial, what they found was patients with the cfDNA response had a markedly improved PFS of 16.4 months versus 4.8 months. So essentially, like, this is a really nice study to set a foundation on which we have to do larger studies to incorporate molecular markers trying to look at cfDNA response to inform treatment strategy, either escalation or de-escalation strategies. So, I thought it was a very interesting study. Dr. Nate Pennell: Yeah. I mean, we always have this question for patients, “Should they get immunotherapy alone or combined with chemo?” and I think this certainly is intriguing, suggesting that there may be ways you can monitor people and perhaps rescue those that aren't going to respond to single agent. I'd like to see a randomized trial against, you know, this strategy, perhaps against everyone getting, say, chemoimmunotherapy or make sure that you're not potentially harming people by doing this strategy. But I agree, it's time to move beyond just observing that cell-free DNA is prognostic and important and start using it to actually guide treatment. Dr. Vamsi Velcheti: Yeah, and I would just caution though, like, you know, I think we need more data, but, however, it's certainly a very interesting piece of data to kind of help inform future trials. So, there was another abstract that caught my attention, and I think this would be a very interesting abstract in the EGFR space. Abstract 8506, "Patritumab Deruxtecan (HER3-DXd) in Resistant EGFR-Mutant Advanced Non-Small Cell Lung Cancer Patients After Third-Generation EGFR TKI," it's the HERTHENA-Lung02 study. What do you think about the results of this study? Dr. Nate Pennell: Yeah, this was, I would say, very widely anticipated and ultimately a little disappointing, despite being a positive trial. So, these are patients with EGFR-mutant non-small cell lung cancer who have progressed after a third-generation EGFR TKI like osimertinib. This is really an area of major unmet need. We do have drugs like amivantamab in this space, but still definitely an area where essentially patients move from having a highly effective oral therapy to being in the realm of chemotherapy as their best option. So, this HER3 antibody-drug conjugate, patritumab deruxtecan, had some good single-arm data for this. And we're sort of hoping this would become an available option for patients. This trial was designed against platinum-doublet chemotherapy in this setting and with a primary endpoint of progression-free survival. And it actually was positive for improved progression-free survival compared to chemo with a hazard ratio of 0.77. But when you look at the medians, you can see that the median PFS was only 5.8 versus 5.4 months. It was really a modest difference between the two arms. And on the interim analysis, it appeared that there will not be a difference in overall survival between the two arms. In fact, the hazard ratio at the interim analysis was 0.98 for the two arms. So based on this, unfortunately, the company that developed the HER3-DXd has withdrawn their application to the FDA for approval of the drug, anticipating that they probably wouldn't get past approval without that overall survival endpoint. So, unfortunately, probably not, at least for the near future, going to be a new option for these patients. Dr. Vamsi Velcheti: Yeah, I think this is a space that's clearly an unmet need, and this was a big disappointment, I should say. I think all of us were going into the meeting anticipating some change in the standard of care here. Dr. Nate Pennell: Yeah, I agree. It was something that I was telling patients, honestly, that I was expecting this to be coming, and so now, definitely a bit of a disappointment. But it happens and, hopefully, it will still find perhaps a role or other drugs with a similar target. Certainly an active area. Well, let's leave the EGFR-mutant space and move into small cell. There were a couple of very impactful studies. And one of them was Abstract 8006, “Lurbinectedin Plus Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer, Primary Results from the Phase III IMforte Trial.” So, what was your impression of this? Dr. Vamsi Velcheti: Yeah, I think this is definitely an interesting study, and small cell, I remember those days when we had barely any studies of small cell at ASCO, and now we have a lot of exciting developments in the small cell space. It's really good to see. The IMforte trial is essentially like a maintenance lurbinectedin trial with atezolizumab maintenance. And the study was a positive trial. The primary endpoint was a PFS, and the study showed improvement in both PFS and OS with the addition of lurbinectedin to atezolizumab maintenance. And definitely, it's a positive trial, met its primary endpoint, but I always am a little skeptical of adding maintenance cytotoxic therapies here in this setting. In my practice, and I'd like to hear your opinion, Nate, most patients with small cell after 4 cycles of a platinum doublet, they're kind of really beaten up. Adding more cytotoxic therapy in the maintenance space is going to be tough, I think, for a lot of patients. But also, most importantly, I think this rapidly evolving landscape for patients with small cell lung cancer with multiple new, exciting agents, actually like some FDA-approved like tarlatamab, also like a lot of these emerging therapeutics like I-DXd and other ADCs in this space. You kind of wonder, is it really optimal strategy to bring on like another cytotoxic agent right after induction chemotherapy, or do you kind of delay that? Or maybe have like a different strategy in terms of maintenance. I know that the tarlatamab maintenance trial is probably going to read out at some point too. I think it's a little challenging. The hazard ratio is also 0.73. As I said, it's a positive trial, but it's just incremental benefit of adding lurbi. And also on the trial, we need to also pay attention to the post-progression second-line treatments, number of patients who received tarlatamab or any other investigational agents.  So I think it's a lot of questions still. I'm not quite sure I'd be able to embrace this completely. I think a vast majority of my patients might not be eligible anyway for cytotoxic chemotherapy maintenance right away, but yeah, it's tough. Dr. Nate Pennell: Yeah. I would call this a single and not a home run. It definitely is real. It was a real overall survival benefit. Certainly not surprising that a maintenance therapy would improve progression-free survival. We've known that for a long time in small cell, but first to really show an overall survival benefit. But I completely agree with you. I mean, many people are not going to want to continue further cytotoxics after 4 cycles of platinum-doublet chemo. So I would say, for those that are young and healthy and fly through chemo without a lot of toxicity, I think certainly something worth mentioning. The problem with small cell, of course, is that so many people get sick so quickly while on that observation period after first-line chemo that they don't make it to second-line treatment. And so, giving everyone maintenance therapy essentially ensures everyone gets that second-line treatment. But they also lose that potentially precious few months where they feel good and normal and are able to be off of treatment. So, I would say this is something where we're really going to have to kind of sit and have that shared decision-making visit with patients and decide what's meaningful to them. Dr. Vamsi Velcheti: Yeah, I agree. The next abstract that was a Late-Breaking Abstract, 8000, “Overall Survival of Neoadjuvant Nivolumab Plus Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer in CheckMate-816.” This was a highly anticipated read-out of the OS data from 816. What did you make of this abstract? Dr. Nate Pennell: Yeah, I thought this was great. Of course, CheckMate-816 changed practice a number of years ago when it first reported out. So, this was the first of the neoadjuvant or perioperative chemoimmunotherapy studies in resectable non-small cell lung cancer. So, just to review, this was a phase 3 study for patients with what we would now consider stage II or stage IIIA resectable non-small cell lung cancer. And they received three cycles of either chemotherapy or chemotherapy plus nivolumab, and that was it. That was the whole treatment. No adjuvant treatment was given afterwards. They went to resection. And patients who received the chemoimmunotherapy had a much higher pathologic complete response rate and a much better event-free survival. And based on this, this regimen was approved and, I think, at least in the United States, widely adopted.  Now, since the first presentation of CheckMate 816, there have been a number of perioperative studies that have included an adjuvant component of immunotherapy – KEYNOTE-671, the AEGEAN study – and these also have shown improved outcomes. The KEYNOTE study with pembrolizumab also with an overall survival benefit. And I think people forgot a little bit about CheckMate-816. So, this was the 5-year overall survival final analysis. And it did show a statistically and, I think, clinically meaningful difference in overall survival with the 3 cycles of neoadjuvant chemo-nivo compared to chemo with a hazard ratio of 0.72. The 5-year overall survival of 65% in the chemo-IO group versus 55% with the chemo alone. So a meaningful improvement. And interestingly, that hazard ratio of 0.72 is very similar to what was seen in the peri-operative pembro study that included the adjuvant component. So, very much still relevant for people who think that perhaps the value of those neoadjuvant treatments might be really where most of the impact comes from this type of approach. They also gave us an update on those with pathologic complete response, showing really astronomically good outcomes. If you have a pathologic complete response, which was more than a quarter of patients, the long-term survival was just phenomenal. I mean, 95% alive at 5 years if they were in that group and suggesting that in those patients at least, the adjuvant treatment may not be all that important.  So, I think this was an exciting update and still leaves very much the open question about the importance of continuing immunotherapy after surgery after the neoadjuvant component. Dr. Vamsi Velcheti: Yeah, I completely agree, Nate. I think the million-dollar question is: “Is there like a population of patients who don't have complete response but like maybe close to complete response?” So, would you like still consider stopping adjuvant IO? I probably would not be comfortable, but I think sometimes, you know, we all have patients who are like very apprehensive of continuing treatments. So, I think that we really need more studies, especially for those patients who don't achieve a complete CR. I think trying to find strategies for like de-escalation based on MRD or other risk factors. But we need more trials in that space to inform not just de-escalation, but there are some patients who don't respond at all to a neoadjuvant IO. So, there may be an opportunity for escalating adjuvant therapies. So, it is an interesting space to watch out for. Dr. Nate Pennell: No, absolutely. Moving to KRAS-mutant space, so our very common situation in patients with non-small cell lung cancer, we had the results of Abstract 8500, “First-Line Adagrasib With Pembrolizumab in Patients With Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer” from the phase 2 portion of the KRYSTAL-7 study. Why was this an interesting and important study? Dr. Vamsi Velcheti: First of all, there were attempts to kind of combine KRASG12C inhibitors in the past with immune checkpoint inhibitors, notably sotorasib with pembrolizumab. Unfortunately, those trials have led to like a lot of toxicity, with increased especially liver toxicity, which was a major issue. This is a phase 2 study of adagrasib in combination with pembrolizumab, and this is a study in the frontline setting in patients with the G12C-mutant metastatic non-small cell lung cancer. And across all the PD-L1 groups, the ORR was 44%, and the median PFS was 11 months, comparable to the previous data that we have seen with adagrasib in this setting. So it's not like a major improvement in clinical efficacy. However, I think the toxicity profile that we were seeing was slightly better than the previous trials in combination with sotorasib, but you still have a fair amount of transaminitis even in the study. At this point, this is not ready for clinical primetime. I don't think we should be using sotorasib or adagrasib in the frontline or even in the second line in combination with checkpoint inhibitors. Combining these drugs with checkpoint inhibitors in the clinical practice might lead to adverse outcomes. So, we need to wait for more data like newer-generation G12C inhibitors which are also being studied in combination, so we'll have to kind of wait for more data to emerge in this space. Dr. Nate Pennell: I agree, this is not immediately practice changing. This is really an attempt to try to combine targeted treatment with immune checkpoint inhibitor. And I agree with you that, you know, it does appear to be perhaps a little bit better tolerated than some of the prior combinations that have tried in this space. The outcomes overall were not that impressive, although in the PD-L1 greater than 50%, it did have a better response rate perhaps than you would expect with either drug alone. And I do think that the company is focusing on that population for a future randomized trial, which certainly would inform this question better. But in the meantime, I agree with you, there's a lot of newer drugs that are coming along that potentially may be more active and better tolerated. And so, I'd say for now, interesting but we'll wait and see. Dr. Vamsi Velcheti: Yeah, so now moving back again to small cell. So, there was a Late-Breaking Abstract, 8008. This is a study of tarlatamab versus chemotherapy as second-line treatment for small cell lung cancer. They presented the primary analysis of the phase III DeLLphi-304 study. What do you think about this? Dr. Nate Pennell: Yeah, I thought this was really exciting. This was, I would say, perhaps the most important lung study that was presented. Tarlatamab is, of course, the anti-DLL3 bispecific T-cell engager compound, which is already FDA approved based on a prior single-arm phase II study, which showed a very nice response rate as a single agent in previously treated small cell lung cancer and relatively manageable side effects, although somewhat unique to solid tumor docs in the use of these bispecific drugs in things like cytokine release syndrome and ICANS, the neurologic toxicities. So, this trial was important because tarlatamab was approved, but there were also other chemotherapy drugs approved in the previously treated space. And so, this was a head-to-head second-line competition comparison between tarlatamab and either topotecan, lurbinectedin, or amrubicin in previously treated small cell patients with a primary endpoint of overall survival. So, a very well-designed trial. And it did show, I think, a very impressive improvement in overall survival with a median overall survival in the tarlatamab group of 13.6 months compared to 8.3 months with chemotherapy, hazard ratio of 0.6. And progression-free survival was also longer at 4.2 months versus 3.2 months, hazard ratio of 0.72. In addition to showing improvements in cancer-related symptoms that were improved in tarlatamab compared to chemotherapy, there was actually also significantly lower rates of serious treatment-related adverse events with tarlatamab compared to chemotherapy. So, you do still see the cytokine release syndrome, which is seen in most people but is manageable because these patients are admitted to the hospital for the first two cycles, as well as a significant number of patients with neurologic side effects, the so-called ICANS, which also can be treated with steroids. And so, I think based upon the very significant improvement in outcomes, I would expect that this should become our kind of standard second-line treatment since it seems to be much better than chemo. However, tarlatamab is definitely a new drug that a lot of places are not used to using, and I think a lot of cancer centers, especially ones that aren't tied to a hospital, may have questions about how to deal with the CRS. So, I'm curious your thoughts on that. Dr. Vamsi Velcheti: Yeah, thank you, Nate. And I completely agree. I think the data looked really promising, and I've already been using tarlatamab in the second-line space. The durability of response and overall, having used tarlatamab quite a bit - like, I participated in some of the early trials and also used it as standard of care - tarlatamab has unique challenges in terms of like need for hospitalization for monitoring for the first few treatments and make sure, you know, we monitor those patients for CRS and ICANS. But once you get past that initial administration and monitoring of CRS, these patients have a much better quality of life, they're off chemotherapy, and I think it's really about the logistics of actually administering tarlatamab and coordination with the hospital and administration in the outpatient setting. It's definitely challenging, but I think it definitely can be done and should be done given what we are seeing in terms of clinical efficacy here. Dr. Nate Pennell: I agree. I think hospital systems now are just going to have to find a way to be able to get this on formulary and use it because it clearly seems to be more effective and generally better tolerated by patients. So, should move forward, I think. Finally, there's an abstract I wanted to ask you about, Abstract 8001, which is the “Neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone in resectable epidermal growth factor receptor-mutated non-small cell lung cancer: The NeoADAURA Study”. And this is one that I think was also fairly highly anticipated. So, what are your thoughts? Dr. Vamsi Velcheti: You know, I wasn't probably surprised with the results, and I believe we were all expecting a positive trial, and we certainly were handed a positive trial here. It's a phase III trial of osimertinib and chemotherapy or osimertinib in the neoadjuvant space followed by surgery, followed by osimertinib. It's a global phase 3 trial and very well conducted, and patients with stage II to stage IIIB were enrolled in the study. And in the trial, patients who had a neoadjuvant osimertinib with or without chemotherapy showed a significant improvement in major pathologic response rates over chemotherapy alone. And the EFS was also positive for osimertinib and chemotherapy, osimertinib monotherapy as well compared to chemotherapy alone. So overall, the study met its primary endpoint, and I think it sheds light on how we manage our patients with early-stage lung cancer. I think osimertinib, we know that osimertinib is already FDA approved in the adjuvant space, but what we didn't really know is how was osimertinib going to work in the neoadjuvant space. And there are always situations, especially for stage III patients, where we are on the fence about, are these patients already close to being metastatic? They have, like, almost all these patients have micrometastatic disease, even if they have stage III. As we saw in the LAURA data, when you look at the control arm, it was like a very short PFS. Chemoradiation does nothing for those patients, and I think these patients have systemic mets, either gross or micrometastatic disease at onset. So, it's really important to incorporate osimertinib early in the treatment course. And I think, especially for the locally advanced patients, I think it's even more important to kind of incorporate osimertinib in the neoadjuvant space and get effective local control with surgery and treat them with adjuvant. I'm curious to hear your thoughts, Nate. Dr. Nate Pennell: I am a believer and have long been a believer in targeted adjuvant treatments, and, you know, it has always bothered me somewhat that we're using our far and away most effective systemic therapy; we wait until after they go through all their pre-op treatments, they go through surgery, then they go through chemotherapy, and then finally months later, they get their osimertinib, and it still clearly improves survival in the adjuvant setting. Why not just start the osimertinib as soon as you know that the patient has EGFR-mutant non-small cell lung cancer, and then you can move on to surgery and adjuvant treatment afterwards? And I think what was remarkable about this study is that all of these patients almost - 90% in each arm - went to surgery. So, you weren't harming them with the neoadjuvant treatment. And clearly better major pathologic response, nodal downstaging, event-free survival was better. But I don't know that this trial is ever going to show an overall survival difference between neoadjuvant versus just surgery and adjuvant treatment, given how effective the drug is in the adjuvant setting. Nonetheless, I think the data is compelling enough to consider this, certainly for our N2-positive, stage IIIA patients or a IIIB who might be otherwise surgical candidates. I think based on this, I would certainly consider that. Dr. Vamsi Velcheti: Yeah, and especially for EGFR, like even for stage IIIB patients, in the light of the LAURA study, those patients who do not do too well with chemoradiation. So you're kind of delaying effective systemic therapy, as you said, waiting for the chemoradiation to finish. So I think probably time to revisit how we kind of manage these locally advanced EGFR patients. Dr. Nate Pennell: Yep, I agree. Dr. Vamsi Velcheti: Nate, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been an exciting ASCO again. You know, we've seen a lot of positive trials impacting our care of non-small cell lung cancer and small cell lung cancer patients. Dr. Nate Pennell: Thanks for inviting me, Vamsi. Always a pleasure to discuss these with you. Dr. Vamsi Velcheti: And thanks to our listeners for your time today. You will find links to all of the abstracts discussed today in the transcript of the episode. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, subscribe wherever you get your podcast. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Vamsi Velcheti   @VamsiVelcheti    Dr. Nathan Pennell   @n8pennell   Follow ASCO on social media:     @ASCO on Twitter     ASCO on Facebook     ASCO on LinkedIn   ASCO on BlueSky   Disclosures:   Dr. Vamsi Velcheti:   Honoraria: ITeos Therapeutics   Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus   Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline   Dr. Nathan Pennell:     Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron    Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi 

Get this full episode and support the pod! ⁠Join our Patreon ⁠for $5 a month for full episodes, bonus eps and exclusive premium content!⁠Join the Discord community⁠Dive into our discord channel to connect with fellow fans, discuss your favorite episodes, and meet the hosts of the show!Apologize for the delay but we've got today's ep filled with lots of bits and lots of laughs! Ollie Hobson and Lauren Summers join us on the pod today to chat'n'prov about palm readings, triple Virgos, ham sub snacks, slip'n'slides and more!FUDGE and Friends with Erin Keif and Jessie Kendall is going down tonight at iO at 8 pm. If you plan on coming, PLZ use code FUDGEFRIEND to get your discount online!Follow Ollie on socials for info on upcoming shows and music!Follow Lauren for updates on where to see her performing around town!Performers:Hosts:⁠ ⁠Damian Anaya⁠⁠,⁠ ⁠Tim Lyons⁠⁠, and⁠ ⁠Dan White⁠⁠